BCG revaccination for healthcare workers in SARS-CoV-2 pandemic

Clinical trial in South Africa to evaluate the potential of BCG as a COVID-19 vaccine. The contributions of the groups under IISA umbrella (Pedro Baptista, Santiago Ramon-García and Rosa Bolea) will be in kind to evaluate in the lung organoid model the potential of the BCG vaccines. Information from the clinical trial will feed model experimentation. This in kind contribution is provided alternative funding sources are secure.

IISA leader for this consortium is Santiago Ramón-García.

Acronym: 
RE-BCG-CoV-19
Author: 
Ramón García, Santiago
Principal researcher: 
Andreas Diacon
Managing entity: 
Otros
Scope: 
Internacional
Entidades participantes: 
Task Foundation-NPC South Africa
Stichting Katholieke Universiteit- Radboudumc (RUMC), Netherlands
Uppsala University, Sweden
Fundación Instituto de Investigación Sanitaria Aragón, Spain
Number of researchers: 
20
Start date: 
04/2020
End date: 
04/2022
Entidad financiadora
Financing entity: 
EDCTP (European & Developing Countries Clinical Trials Partnership)
Call: 
RIA2020EF-2968 (Mobilisation of research funds for COVID-19 as a Public Health Emergency)
Presupuesto
Total budget: 
500.000€